Data and analysis business joins forces with university
Register for free to receive latest news stories direct to your inboxRegister
DeepMatter, an AIM-listed company focusing on digitising chemistry, has been selected as a partner for the University of Leeds.
It follows a £1.4m Engineering and Physical Sciences Research Council investment received to develop automated precision manufacturing approaches in collaboration with the University of Sheffield, AstraZeneca, Somaserve and Samsung.
DeepMatter will provide its DigitalGlassware® platform, a cloud-based platform that allow chemists to share data in real-time and develop digitally enabled scale-up of advanced nanoparticle products.
Nanoparticles are an important component in ensuring safe and effective drug delivery of new-generation (mRNA) vaccines and certain anti-cancer drugs.
The technology to digitally enable the scale-up of advanced nanoparticle products will be a sustainable, cost-effective alternative to the current method of production, and brings innovation beyond a laboratory setting across several manufacturing environments.
In addition to the cloud-based software, DeepMatter will provide its proprietary low-footprint sensor package, DeviceX, which provides a new perspective on chemical reaction data, as well as a hardware device to interface with the continuous platforms at the University of Leeds.
Dr Nicholas Warren, from the School of Chemical and Process Engineering at the University of Leeds, is leading the research alongside colleagues Dr Richard Bourne and Dr Thomas Chamberlain from the School of Chemistry, and researchers from the University of Sheffield.
Mark Warne, CEO of DeepMatter Group, said: “We are delighted to be partnering with both the key opinion leaders at the University of Leeds and University of Sheffield, as well as large pharma companies.
“Our DigitalGlassware® platform will be used to provide a unique perspective on the data helping with both discovery and productivity gains for chemical reactions forming nanoparticles – an essential component in delivering effective mRNA vaccines.”
Dr Warren, Associate Professor at the University of Leeds, added: “Sustainable and cost-effective scale-up is yet to be achieved with nanomaterials production, so to address this issue we are developing platform technologies with advanced chemical reactors underpinned by computational intelligence.
“The data captured by DigitalGlassware® in real-time allows us to use ML and AI directed decisions contributing to self-optimising reactions helping us to build up an understanding of the processes and fine-tune reaction conditions leading to a scaled-up, commercially viable production of advanced nanoparticle products.”